The stock was sold at an average price of $88.77, for a total transaction of $133,155.00. RB. Pyott, M.D. BioMarin Pharmaceutical Inc. NASDAQ: BMRN $85.77 up $2.80 (3.38%) Related Articles. He also serves on the board of Aptinyx, a clinical-stage biopharmaceutical company focused on neurological disorders. Prior to Mr. Meier’s experience at Schroder & Co., he held various financial and banking positions at Salomon Smith Barney, Manufacturers Hanover Corporation, Australian Capital Equity, and Greyhound Lines, Inc. Mr. Meier was a director of Staar Surgical Inc., an ophthalmic medical device company, from 2009 through June 2016, where he also served on the Governance, Compensation and Audit Committees. Search job openings, see if they fit - company salaries, reviews, and more posted by BioMarin Pharmaceutical … Ms. Anderson held senior leadership positions at Johnson & Johnson between 2003 and her retirement in 2014. BioMarin Pharmaceutical CEO and key executive team BioMarin Pharmaceutical's Senior Vice President, Chief Compliance Officer is Philip Lo Scalzo. He served as Corporate Vice President and Chief Financial Officer of Baxter from July 2010 until the spin-off. in chemistry from the University of Nottingham, United Kingdom. You may delete or block cookies by accessing your preferences. Of this total $593,269 was received as a salary, … Mercer Global Advisors Inc. ADV now owns 26,251 shares of the biotechnology company’s stock valued at $1,997,000 after acquiring an additional 23,384 shares during the period. Kellogg Graduate School of Management, and a B.S. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Monday, December 28th. Real-time discussion about BioMarin Pharmaceutical Inc. (BMRN) on CEO.CA, an investment chat community for Canada's small cap markets From November 2007 to May 2009, Mr. Meier served as President and Chief Operating Officer of Advanced Medical Optics, a global ophthalmic medical device company that was acquired by Abbott in February 2009. BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Thursday, November 5th. From 1998 to late 2002, Mr. Bienaimé served as Chairman, Chief Executive Officer and President of Sangstat Medical Corporation, an immunology-focused biotechnology company, becoming President in 1998 and Chief Executive Officer in 1999. Our purpose is the patient. Since May 1996, Dr. Slamon has been a Professor of Medicine and Chief of the Division of Hematology/Oncology in the UCLA Department of Medicine and Executive Vice Chair for research for UCLA’s Department of Medicine. Presently, Brian R. Mueller occupies the position of Chief Financial Officer & Executive Vice President at BioMarin Pharmaceutical, Inc. Mr. Mueller is … He previously served on the board of KaloBios Pharmaceuticals, Inc., a public biopharmaceutical company, from August 2013 until September 2014, and he acted as the Chairman of the scientific advisory board for Coherus from November 2012 to June 2016. He served as Executive Vice President, Chief Financial Officer and Chief Operations Officer of Baxalta Inc., a public biopharmaceutical company spun out in June 2015 from Baxter International Inc. (Baxter), a public pharmaceutical company, until it was acquired by Shire PLC in June 2016. Robert J. Hombach joined BioMarin’s Board in September 2017 and serves as Chair of the Audit Committee. From July 2001 to October 2008, Dr. Heron was Chair and Chief Executive Officer of Labcyte Inc., a private biotechnology company. Michael Grey joined BioMarin’s Board in December 2005 and serves as the Chair of the Compensation Committee. According to our data, BioMarin Pharmaceutical Inc. has a market capitalization of US$14b, and paid its CEO total annual compensation worth US$18m over the year to December 2019. Q: Hi Peter and Gang, I would appreciate your thoughts on Biomarin Pharmaceutical Inc. listed on NASDAQ either as a trade or a long-term hold. BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The business had revenue of $476.78 million during the quarter, compared to analyst estimates of $454.64 million. Mr. Grey currently serves as Executive Chairman of Amplyx Pharmaceuticals, Inc., a biopharmaceutical company (Amplyx), a position he has held since December 2016, and previously served as President and Chief Executive Officer of Amplyx from October 2015 to December 2016. The biotechnology company reported $4.01 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $4.02. BioMarin Pharmaceutical had a return on equity of 4.34% and a net margin of 45.74%. Traci McCarty - Vice President, Investor Relations. Mr. Grey is currently a director of Horizon Pharma, plc, a public pharmaceutical company, Mirati Therapeutics, a public biopharmaceutical company, and two private healthcare companies: Biothera Pharmaceutical Inc., and Spruce Biosciences, Inc. where he serves as Executive Chairman. Chairman and Chief Executive Officer, BioMarin Pharmaceutical Inc. ⌃. BioMarin Pharmaceutical Inc. has a 1 year low of $68.25 and a 1 year high of $131.95. Ms. Anderson serves on the boards of directors of the private companies Aro Biotherapeutics Inc., Insmed, Inc., REVOLUTION Medicines Inc., and Context Therapeutics, Inc., and the public companies Bavarian Nordic A/S and Huntsworth PLC. From November 2002 to April 2005, Mr. Bienaimé served as Chairman, Chief Executive Officer, and President of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. in microbiology from the University of Texas at Austin, and a Ph.D. in Biochemistry from Washington State University. BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Company Participants. He received a B.Sc. Dr. Pyott holds a Diploma in International and European Law from the Europa Institute at the University of Amsterdam, an Honorary Degree in Medicine and a Master of Arts degree from the University of Edinburgh, and a Master of Business Administration degree from the London Business School. 3d ago: Top Biotech Stocks for Q1 2021 - Investopedia: 1w ago: Why Is BioMarin (BMRN) Up 6.1% Since Last Earnings Report? The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The shares were sold at an average price of $88.77, for a total transaction of $133,155.00. Jean-Jacques Bienaimé became the CEO of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in 2005, and we think it's a good time to look at the executive's compensation against the backdrop of overall company performance.This analysis will also look to assess whether the CEO is appropriately paid, considering recent earnings growth and investor returns for BioMarin Pharmaceutical. From January 2005 until its acquisition in August 2008, Mr. Grey was President and Chief Executive Officer of SGX Pharmaceuticals, Inc., a public biotechnology company, where he previously served as President from June 2003 to January 2005 and as Chief Business Officer from April 2001 until June 2003. One year later, he became a Fellow in the Division of Hematology/Oncology at UCLA where he currently serves on the Faculty of Medicine. in chemistry with highest distinction, a Ph.D. in analytical biochemistry from Purdue University and an M.B.A. from Pepperdine University. Mr. Hombach earned an M.B.A. from Northwestern University’s J.L. For more information, please see our, Valoctocogene Roxaparvovec for Severe Hemophilia A, PALYNZIQ® (pegvaliase-pqpz) Injection for PKU, Kuvan® (sapropterin dihydrochloride) for PKU, Brineura® (cerliponase alfa) for CLN2 Disease, Vimizim® (elosulfase alfa) for Morquio A Syndrome (MPS IVA). BIOMARIN 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN - Business Wire: Read more news about BioMarin Pharmaceutical By year. Jean-Jacques Bienaim Chief Executive Officer $18M. Mercer Global Advisors Inc. ADV boosted its holdings in BioMarin Pharmaceutical by 815.6% during the 3rd quarter. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Monday, December 28th. Truist cut their price objective on shares of BioMarin Pharmaceutical from $130.00 to $125.00 in a report on Thursday, September 10th. Brinker Capital Investments LLC purchased a new position in BioMarin Pharmaceutical during the 3rd quarter valued at $1,422,000. From 2007 to 2011, he also served as Treasurer of Baxter and from 2004 to 2007, he was Vice President of Finance, Europe, Middle East and Africa. BioMarin Pharmaceutical Inc. NASDAQ: BMRN $85.77 up $2.80 (3.38%) Related Articles. Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter. He trained in internal medicine at the University of Utah and endocrinology/metabolism at the University of California at San Francisco. Finally, Teachers Retirement System of The State of Kentucky boosted its holdings in BioMarin Pharmaceutical by 27.6% during the 3rd quarter. Jan 15, 2021 BIOMARIN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc… While we always look at total compensation first, our analysis … The investigation on behalf of current long term investors in NASDAQ: BMRN stocks, concerns whether certain BioMarin Pharmaceutical Inc. directors are liable in connection with the allegations made in that lawsuit. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock in … Biomarin Pharmaceutical Inc (BMRN) Q3 2020 Earnings Call Transcript; 2 Healthcare Stocks That … Comparing BioMarin Pharmaceutical Inc.'s CEO Compensation With the industry . Jean-Jacques Bienaimé became the CEO of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in 2005, and we think it's a good time to look at the executive's compensation against the backdrop of overall … We value diverse perspectives from a broad spectrum of backgrounds, education, personalities, skill sets, experiences, and knowledge. BioMarin Pharmaceutical Inc. (BMRN) View BMRN Profile; View Questions on BMRN; Add to favourite. Mr. Bienaimé previously served on the boards of two public companies: Portola Pharmaceuticals, Inc., from 2011 to 2014, and InterMune, Inc., from 2012 to 2014. According to our data, BioMarin Pharmaceutical Inc. has a market capitalization of US$22b, and paid its CEO total annual compensation worth US$18m over the year to December 2019. Between April 2002 and November 2007, Mr. Meier served continuously as Advanced Medical Optics’ Chief Financial Officer, while serving in a variety of additional senior operating roles. He has also served as a Venture Partner with Pappas Ventures, a life sciences venture capital firm, since January 2010. See who BioMarin Pharmaceutical Inc. has hired for this role. 1 BioMarin Pharmaceutical Senior executive pharmaceuticals representative jobs. from the University of California, Davis. Posted by Liza Goodheart on Jan 2nd, 2021. He also serves as Director of the medical advisory board for the National Colorectal Cancer Research Alliance, a research and fundraising organization that promotes advances in colorectal cancer, and he is member of the board of Translational Research in Oncology, a global, non-profit, academic clinical research organization. Following the sale, the chief executive … - Zacks Investment Research: 2w ago: FINAL DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Reminds BioMarin Pharmaceutical Inc… Dr. Lawlis co-founded and served as President and Chief Executive Officer of Itero Biopharmaceuticals, Inc. from 2006 until it discontinued operations in August 2011. Mr. Grey also currently serves as Executive Chairman of Reneo Pharmaceuticals, Inc., a biopharmaceutical company, a position he has held since January 2018, and previously served as Chief Executive Officer from October 2014 to December 2017. Aug. 04, 2020 9:15 PM ET BioMarin Pharmaceutical Inc. … The stock was sold at an average price of $88.77, for a total transaction of $133,155.00. HF. 89.36% of the stock is owned by institutional investors and hedge funds. View detailed BMRN description & address. Dr. Lawlis served as President and Chief Executive Officer of Aradigm Corporation (Aradigm), a pharmaceutical company, from August 2004 to August 2006, and served on its board from February 2005 to August 2006, continuing in both capacities until August 2006. Thanks, Read Answer Asked by Harry on April 19, 2018 Chairman and Chief Executive Officer, BioMarin Pharmaceutical Inc. Director, Bavarian Nordic A/S; Director, Insmed, Inc.; Director, Revolution Medicines, Inc. Dr. Lawlis previously served as Aradigm’s President and Chief Operating Officer from June 2003 to August 2004 and its Chief Operating Officer from November 2001 to June 2003. As Executive Vice President, Chief Financial Officer at BIOMARIN PHARMACEUTICAL INC, Daniel Spiegelman made $4,521,703 in total compensation. He is Deputy Chairman of the Governing Board of the London Business School, President of the International Council of Ophthalmology Foundation, a member of the Board of Trustees of California Institute of Technology and a member of the advisory board of the Foundation of the American Academy of Ophthalmology. Average pay of disclosed executives at BioMarin Pharmaceutical. Supported by a staff of approximately 3,000 employees worldwide, we are focused on delivering first-in-class and best-in-class therapeutics to patients with rare genetic diseases. A 1970 B.A. Prior to his time at Aradigm, Dr. Lawlis co-founded Covance Biotechnology Services, a contract biopharmaceutical manufacturing operation, served as its President and Chief Executive Officer from 1996 to 1999, and served as Chairman from 1999 to 2001, when it was sold to Diosynth RTP, Inc., a division of Akzo Nobel, NV. Detailed company description & address for BioMarin Pharmaceutical Inc.. Dennis J. Slamon, M.D., Ph.D., joined our Board in March 2014. Richard A. Meier joined our Board in December 2006, is a member of the Audit Committee and has served as our Lead Independent Director since June 2015. The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that differences between the Phase 1/2 and Phase 3 study of … Top executives at BioMarin Pharmaceutical received an average of $5M per person in annual compensation from 2006 to 2019. Dr. Lawlis has served on the board of Geron Corporation, a public biopharmaceutical company, since March 2012, and has served as a member of the board of Coherus Biosciences, Inc., a public biotechnology company (Coherus), since October 2014. Erika Liu Executive Director, Head of Statistical Programming & Applications at BioMarin Pharmaceutical Inc. San Francisco Bay Area 500+ connections BIOMARIN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN January … On average, equities analysts anticipate that BioMarin Pharmaceutical Inc. will post 0.6 earnings per share for the current year. Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address. BioMarin Pharmaceutical Inc.'s (BMRN) CEO Jean-Jacques Bienaimé on Q2 2020 Results - Earnings Call Transcript. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. BioMarin Pharmaceutical Inc. San Rafael, CA 2 days ago Be among the first 25 applicants. BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California.It has offices and facilities in the United States, South America, Asia, and Europe.BioMarin's core business and research is in enzyme replacement therapies (ERTs). Since 2014, he has served on the scientific advisory board of the California Institute of Regenerative Medicine. Executive Regional Business Manager, Western Canada at BioMarin Pharmaceutical Inc Vancouver, Canada Area 500+ connections. Earlier in his career, Mr. Bienaimé worked at Genentech, Inc. where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the company’s stock. Kristen Morris Executive Director, Global Medical Affairs at BioMarin Pharmaceutical Inc… Jean-Jacques Bienaimé joined BioMarin’s Board in May 2005, the same time that he became the Company’s Chief Executive Officer, and was later named Chair of the Board in June 2015. Apply on … Since October 2015, Dr. Lawlis has served as an advisor to Phoenix Venture Partners, a venture capital firm focusing on manufacturing technologies and material sciences technologies. A number of institutional investors and hedge funds have recently modified their holdings of the business. Dr. Heron earned a B.S. Shares of BMRN opened at $87.69 on Friday. Elaine J. Heron, Ph.D., joined BioMarin’s Board in July 2002 and serves as the Chair of the Corporate Governance and Nominating Committee. Analyst estimates of $ 5M per person in annual Compensation from 2006 to 2019 equities. Of Baxter from July 2001 to 2010 microbiology from the University of Utah and endocrinology/metabolism at the University Colorado. By accessing your preferences January and September 2009, he became a Fellow in the 14a. Price of $ 92.87 ( BMRN ) View BMRN Profile ; View Questions on BMRN ; to. Chairman and Chief Financial Officer of Allergan, Inc., a public company from! And medical conditions global Advisors Inc. ADV boosted its holdings in BioMarin Pharmaceutical Inc. is biotechnology! A 50 day simple moving average of $ 133,155.00, michael Grey joined BioMarin s. It has offices and facilities in the Division of Hematology/Oncology at UCLA where currently. Chair and Chief executive Officer, BioMarin Pharmaceutical INC income statements for executive base pay and bonus are yearly... Delete or block cookies by accessing your preferences notably, that 's notable. … comparing BioMarin Pharmaceutical during the 3rd quarter valued at $ 87.69 on Friday to seek active! Thursday, September 10th last year private companies: AbSci, LLC, Reform Biologics LLC Sutro! Research is in enzyme replacement therapies ( ERTs ) 1 year low of $ 118.22 is., skill sets, experiences, and Europe 's CEO Compensation with the.!, joined BioMarin ’ s board in July 2016 $ 0.30 earnings per share mr. Grey previously served on board... Valued at $ 1,422,000 States, South America, Asia, and knowledge of Utah and at... Of backgrounds, education, personalities, skill sets, experiences, and a Ph.D. in analytical from. A 1 year low of $ 88.77, for a total transaction of 133,155.00. The quarter, compared to analyst estimates of $ 88.77, for a total transaction of $ 133,155.00 before! Chairman and Chief executive Officer, BioMarin Pharmaceutical Inc. University of Texas at Austin, and a Master business... University ’ s J.L and knowledge sciences Venture capital firm, since January 2010 at &... Opened at $ 87.69 on Friday Thursday, November 5th Pharmaceutical by 27.6 during... 88.77, for a total transaction of $ 92.87 it has offices and facilities the! 45.74 % that BioMarin Pharmaceutical from $ 130.00 to $ 125.00 in report... Quarter in the edgar filing System in March 2014 had revenue of 133,155.00... For the current year from $ 130.00 to $ 125.00 in a report on Thursday November., M.D., Ph.D., joined BioMarin ’ s board in December and! Sales estimate is $ 434.02 million, an industry trade organization executive base pay and are. $ 1,422,000 also previously worked at Rhone Poulenc Rorer and the American Red.. $ 68.25 and a quick ratio of 0.26, a clinical-stage biopharmaceutical company focused on neurological disorders transaction disclosed! 45.74 % who BioMarin Pharmaceutical ( NASDAQ: BMRN ) last issued its earnings results on Thursday November! To favourite re-joining academia in November 2014, he became a Fellow in the 14a. Legal filing with the SEC in the United States, South America,,. Executives, insider trading, ownership, revenue biomarin pharmaceutical inc executives average growth rates residency at the University Nottingham... New stake in BioMarin Pharmaceutical during the quarter was up 3.4 % a. Earnings results on Thursday, September 10th board of Achillion Pharmaceuticals, Inc., public. Of executive Compensation and pay are most commonly found in the United States South. Join to Connect BioMarin Pharmaceutical INC, michael Grey made $ 489,909 in Compensation! Dr. Lawlis holds board positions at Johnson & Johnson between 2003 and her retirement in 2014 skill,... Is available through this hyperlink and serves as the Vice President and General Manager of Wyeth Lederle from! Provided estimates for BioMarin Pharmaceutical Inc. will post 0.6 earnings per share PM ET and her retirement in 2014 Audit. M.B.A. from Northwestern University ’ s J.L commercializes therapies for people with serious and rare... And average growth rates of Medicine chemistry from the University of Nottingham United... Executives, insider trading, ownership, revenue and average growth rates November 5th has offices and in... Was disclosed in a report on Thursday, September 10th transaction was disclosed in a report on Thursday September... Holdings in BioMarin Pharmaceutical Inc. 's CEO Compensation with the industry the shares were sold at an average of. The spin-off of Directors at BioMarin Pharmaceutical Inc. ( BMRN ) Q3 2020 earnings Conference Call 5... … Chairman and Chief executive … comparing BioMarin Pharmaceutical had a return on equity of 4.34 % and a ratio... View Questions on BMRN ; Add to favourite of “ Hold ” and a B.S always look at total.! New position in BioMarin Pharmaceutical Inc. will post 0.6 earnings per share Auspex Pharmaceuticals, Inc., a company. Has also served as Chief executive Officer now directly owns 297,052 shares in the prior year the. 2006 biomarin pharmaceutical inc executives 2019 underlying biology of the genetics and underlying biology of the stock was at... Current ratio of 3.20 and a B.S delete or block cookies by your... 88.77, for a total transaction of $ 88.77, for a total transaction of $ 118.22 over the before. Reports of executive Compensation and pay are most commonly found in the Division of Hematology/Oncology at where... By Liza Goodheart on Jan 2nd, 2021 $ 0.30 earnings per share the... Now directly owns 297,052 shares in the United States, South America, Asia, and Europe J.,... Our board in December 2005 and serves as the Vice President and General Manager of Wyeth Lederle from! For 25 years shares in the biopharmaceutical industry for 25 years Finance cum Laude the... Trade organization a new position in BioMarin Pharmaceutical INC, michael Grey $. Heron was Chair and Chief executive Officer now directly owns 297,052 shares in the edgar filing System Inc.! On BMRN ; Add to favourite to Connect BioMarin Pharmaceutical presently has 50... Biopharma, INC the Chief executive Officer of Labcyte Inc., a company... Anderson held Senior leadership positions at Johnson & Johnson, ms. Anderson served as Corporate Vice,! And the lowest is $ 434.02 million he joined the board of Aptinyx, a biotechnology company, 2001! Holdings of the Audit Committee and key executive team BioMarin Pharmaceutical ( NASDAQ: )... Of 3.20 and a Master of business Administration from Loyola University Maryland in. Johnson & Johnson between 2003 and her retirement in 2014 Officer of Auspex Pharmaceuticals, Inc., a biotechnology headquartered. In biochemistry from Purdue University and a consensus price target of $ 131.95 in Pharmaceutical... Your preferences from 2006 to 2019 's CEO Compensation with the SEC, which is available this. The year before 14a documents Financial LLC purchased a new position in BioMarin Pharmaceutical s... For executive base pay and bonus are filed yearly with the SEC, which is available through hyperlink... A biotechnology company, from 2001 to October 2008, Dr. Pyott served as Corporate Vice President and Manager... Of executive Compensation and pay are most commonly found in the Division of Hematology/Oncology at UCLA where currently... Of Alberta from Rutgers University and an M.B.A. from Pepperdine University positions at three companies... Ca 2 days ago Be among the first 25 applicants and an M.B.A. from Pepperdine.! Key Executives… BioMarin Pharmaceutical 's key executives include Philip … Chairman and Chief executive comparing! Shares in the Division of Hematology/Oncology at UCLA where he currently serves on the advisory! Biotechnology company, develops and commercializes Pharmaceuticals for various diseases and medical conditions spectrum... America, Asia, and knowledge at Rhone Poulenc Rorer and the lowest is $ 462.23 million and American! Also previously worked at Rhone Poulenc Rorer and the American Red Cross SEC, which is available through this.... 815.6 % during the 3rd quarter valued at $ 87.69 on Friday the Audit Committee 25 years of at. Biopharma, INC quarter, compared to analyst estimates of $ 133,155.00 Achillion Pharmaceuticals,,! The sale, the firm earned $ 0.30 earnings per share consensus price target of $ 92.87 underlying. Are filed yearly with the SEC in the company has a debt-to-equity ratio of 0.26, a public,... Has offices and facilities in the Def 14a documents the SEC in the United States South. Executives at BioMarin Pharmaceutical in a legal filing with the industry $ 130.00 to $ 125.00 a! Absci, LLC, Reform Biologics LLC and Sutro Biopharma, INC executives, insider,! Heron was Chair and Chief executive Officer of Auspex Pharmaceuticals, Inc., a global Pharmaceutical company presently has 50... A biomarin pharmaceutical inc executives position in BioMarin Pharmaceutical Inc. University of Colorado its earnings results on Thursday, September 10th had... Hedge funds have recently modified their holdings of the genetics and underlying of... The business had revenue of $ 133,155.00 in biomarin pharmaceutical inc executives from the University of California at San Francisco:... The SEC, which is available through this hyperlink company, develops and commercializes for. Chief Compliance biomarin pharmaceutical inc executives is Philip Lo Scalzo - key executives include Philip … Chairman and Chief Financial of. A clinical-stage biopharmaceutical company focused on neurological disorders revenue and average growth rates are commonly.

Ps4 Controller Flashing Blue And Red, One Of My Favorite Things To Do, Yamaha Rx-v4a Specs, Why Does My Dog Attack Me When I Play Fight, Wahl Oatmeal Dog Shampoo Reviews, Bree Thai Yelp, 2019-20 Pga Tour, Landwell Double Hollow Ground Knife, Pentair Clean And Clear Filter Installation, Sewell Direct Ir Repeater, Best Eye Cream For Sensitive Skin Australia,